Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Novel HRS9531 shows promise as treatment for obesity in Chinese adults

17 Jul 2024 bởi

Once-weekly treatment with HRS9531, a novel dual GLP-1* and GIP** receptor agonist, resulted in substantial reductions in body weight among Chinese patients with obesity, according to a study presented at ADA 2024.

Novel HRS9531 shows promise as treatment for obesity in Chinese adults

Original New Drug Application Approvals by US FDA (1-15 July 2024)

New drug applications approved by US FDA as of 1-15 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 July 2024)

Automated insulin delivery system beneficial for T2D management

An automated insulin delivery (AID) system appears to improve clinical outcomes in people with type 2 diabetes (T2D), with the pivotal SECURE-T2D trial showing substantial improvements in glycated haemoglobin, total daily insulin dose, and diabetes distress, without increasing the risk of hypoglycaemia.

Automated insulin delivery system beneficial for T2D management

16 Jul 2024

Breastfeeding may prevent development of JSpA in infants

Infant factors affecting the microbiome appears to influence the occurrence of juvenile spondyloarthritis (JSpA), suggests a study, noting a link between exclusive breastfeeding and lower odds of JSpA.

Breastfeeding may prevent development of JSpA in infants

Eating more fibre-rich foods, less red meat and sugar may prolong life expectancy

Changing your usual eating pattern to one that is focused on longevity can bring substantial increases in life expectancy (LE), suggests a study that involved seven countries. These dietary changes include more whole grains, legumes, and nuts and less red/processed meats, sugars, and sugar-sweetened beverages.

Eating more fibre-rich foods, less red meat and sugar may prolong life expectancy

Weight gain tied to hypertension in patients on methadone maintenance treatment

The occurrence of hypertension in patients with opioid use disorder receiving methadone maintenance treatment (MMT) is associated with weight gain, reports a study.

Weight gain tied to hypertension in patients on methadone maintenance treatment

16 Jul 2024

Pemvidutide gains MOMENTUM in phase II obesity trial

Pemvidutide, an investigational, peptide-based GLP-1/glucagon dual receptor agonist, gains traction in the booming obesity drug market, delivering significant weight loss reductions in nondiabetic individuals with overweight or obesity in the phase II MOMENTUM trial.

Pemvidutide gains MOMENTUM in phase II obesity trial

16 Jul 2024

Ph+ ALL: 1L ponatinib ups MRD-negative CR at end of induction vs imatinib

Minimal residual disease (MRD)–negative complete remission (CR) rate at end of induction is significantly higher in adult patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukaemia (ALL) treated with ponatinib vs imatinib combined with reduced-intensity chemotherapy, results of the phase III PhALLCON trial have shown.

Ph+ ALL: 1L ponatinib ups MRD-negative CR at end of induction vs imatinib

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease

Use of glucagon-like peptide-1 receptor agonist (GLP-1RA) appears to reduce the risk of inflammatory bowel disease (IBD)-related surgery in patients with type 2 diabetes mellitus (T2DM) and concomitant ulcerative colitis (UC) or Crohn’s disease (CD), according to a retrospective study.

GLP-1RA treatment for T2DM may lower risk of surgery in inflammatory bowel disease